The morphine-sparing effect of continuous intra-articular infusion of bupivacaine following knee arthroplasty - a randomised double-blind placebo-controlled trial
Completed
- Conditions
- Signs and Symptoms: PainSigns and SymptomsPain
- Registration Number
- ISRCTN62584127
- Lead Sponsor
- Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
The study population will consist of patients admitted by the Department of Orthopaedics, QEH, for unilateral primary knee arthroplasty who are willing to take part in the study
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain score, sedation score, PCA morphine consumption and co-analgesic consumption will be noted postoperatively at regular intervals.
- Secondary Outcome Measures
Name Time Method ot provided at time of registration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bupivacaine's morphine-sparing effect in post-arthroplasty pain management?
How does continuous intra-articular bupivacaine infusion compare to standard multimodal analgesia after knee arthroplasty?
Are specific inflammatory biomarkers predictive of analgesic response to local anesthetic infusions in orthopedic surgery?
What adverse events are associated with prolonged bupivacaine administration in joint replacement patients?
How do liposomal bupivacaine formulations compare to continuous infusion techniques in postoperative pain control?